Contact
searchSearch
HMP Global

Parkinson Disease Topic Center

illustration of a test
Quiz
Which factors increase the risk of late-onset epilepsy (LOE) in people with cognitive decline?
04/23/2025
Do you remember the risk factors for late-onset epilepsy (LOE) in patients with cognitive decline?
Do you remember the risk factors for late-onset epilepsy (LOE) in patients with cognitive decline?
Do you remember the risk factors...
04/23/2025
Neurology
Neurons in the brain
News
Risk Factors for Late-Onset Epilepsy in Patients With Cognitive Decline Identified
04/21/2025
Jolynn Tumolo
Late-onset epilepsy (LOE) risk factors in people with cognitive decline include Parkinson disease, early-onset dementia (before age 60), poor cognition, stroke or transient ischemic attacks, Alzheimer disease, and the APOE4 allele.
Late-onset epilepsy (LOE) risk factors in people with cognitive decline include Parkinson disease, early-onset dementia (before age 60), poor cognition, stroke or transient ischemic attacks, Alzheimer disease, and the APOE4 allele.
Late-onset epilepsy (LOE) risk...
04/21/2025
Neurology
Take the Quiz!
Quiz
Parkinson Disease Diagnosis: Test Your Knowledge of Clinical Criteria
03/07/2025
Meagan Thistle
Think you know the key clinical features required to diagnose Parkinson disease? Put your knowledge of MDS criteria to the test!
Think you know the key clinical features required to diagnose Parkinson disease? Put your knowledge of MDS criteria to the test!
Think you know the key clinical...
03/07/2025
Neurology
An illustration of a brain against a blue background, with a deep brain stimulation device connected via electrodes
News
FDA Approves ‘Self-Adjusting’ DBS Therapy for Parkinson Disease
02/25/2025
Brionna Mendoza
On Monday, the United States Food and Drug Administration (FDA) approved an adaptive deep brain stimulation (aDBS) technology for people living with Parkinson disease (PD).
On Monday, the United States Food and Drug Administration (FDA) approved an adaptive deep brain stimulation (aDBS) technology for people living with Parkinson disease (PD).
On Monday, the United States...
02/25/2025
Neurology
fda building sign
News
FDA Approves Apomorphine Drug-Device for Movement Symptoms in Parkinson Disease
02/04/2025
Brionna Mendoza
The US Food and Drug Administration (FDA) approved a drug-device combination to treat movement-related symptoms in advanced Parkinson disease.
The US Food and Drug Administration (FDA) approved a drug-device combination to treat movement-related symptoms in advanced Parkinson disease.
The US Food and Drug...
02/04/2025
Neurology
a patient with parkinson disease steadies a tremoring hand and wrist
News
Propranolol Reduces Tremors in Parkinson Disease Patients
01/16/2025
Jolynn Tumolo
The beta-blocker propranolol reduces Parkinson disease (PD) tremor in both stressful and resting conditions, according to results from a placebo-controlled crossover trial published in the Annals of Neurology.
The beta-blocker propranolol reduces Parkinson disease (PD) tremor in both stressful and resting conditions, according to results from a placebo-controlled crossover trial published in the Annals of Neurology.
The beta-blocker propranolol...
01/16/2025
Neurology
FDA approval stamp
News
FDA Approves Infusion Treatment for Advanced Parkinson Disease in Adults
10/18/2024
Meagan Thistle
AbbVie’s VYALEV (foscarbidopa and foslevodopa), the first 24-hour continuous subcutaneous infusion of levodopa-based therapy for managing motor fluctuations in adults with advanced Parkinson disease (PD), approved by the FDA.
AbbVie’s VYALEV (foscarbidopa and foslevodopa), the first 24-hour continuous subcutaneous infusion of levodopa-based therapy for managing motor fluctuations in adults with advanced Parkinson disease (PD), approved by the FDA.
AbbVie’s VYALEV (foscarbidopa...
10/18/2024
Neurology
A person walks down a boarded path with sunlight and trees in the background
News
Phase 3 TEMPO-1 Trial Reports Positive Results on Tavapadon for Parkinson Disease
10/09/2024
Brionna Mendoza
Tavapadon, an investigational D1/D5 dopamine receptor partial agonist for Parkinson disease (PD), met both the primary and secondary endpoints in the phase 3 TEMPO-1 clinical trial.
Tavapadon, an investigational D1/D5 dopamine receptor partial agonist for Parkinson disease (PD), met both the primary and secondary endpoints in the phase 3 TEMPO-1 clinical trial.
Tavapadon, an investigational...
10/09/2024
Neurology
News
Parkinson Disease Risk Elevated in Patients With Upper GI Mucosal Damage
09/30/2024
Jolynn Tumolo
A history of upper gastrointestinal mucosal damage is associated with a 76% increased risk of subsequent Parkinson disease (PD), according to a study published online in JAMA Network Open.
A history of upper gastrointestinal mucosal damage is associated with a 76% increased risk of subsequent Parkinson disease (PD), according to a study published online in JAMA Network Open.
A history of upper...
09/30/2024
Neurology
Pop quiz written on a blackboard with white chalk
Quiz
Anxiety and Parkinson Disease Development in Older Adults
09/24/2024
Test your knowledge of recent research with this quiz!
Test your knowledge of recent research with this quiz!
Test your knowledge of recent...
09/24/2024
Neurology

News

Neurons in the brain
News
Risk Factors for Late-Onset Epilepsy in Patients With Cognitive Decline Identified
04/21/2025
Jolynn Tumolo
Late-onset epilepsy (LOE) risk factors in people with cognitive decline include Parkinson disease, early-onset dementia (before age 60), poor cognition, stroke or transient ischemic attacks, Alzheimer disease, and the APOE4 allele.
Late-onset epilepsy (LOE) risk factors in people with cognitive decline include Parkinson disease, early-onset dementia (before age 60), poor cognition, stroke or transient ischemic attacks, Alzheimer disease, and the APOE4 allele.
Late-onset epilepsy (LOE) risk...
04/21/2025
Neurology
An illustration of a brain against a blue background, with a deep brain stimulation device connected via electrodes
News
FDA Approves ‘Self-Adjusting’ DBS Therapy for Parkinson Disease
02/25/2025
Brionna Mendoza
On Monday, the United States Food and Drug Administration (FDA) approved an adaptive deep brain stimulation (aDBS) technology for people living with Parkinson disease (PD).
On Monday, the United States Food and Drug Administration (FDA) approved an adaptive deep brain stimulation (aDBS) technology for people living with Parkinson disease (PD).
On Monday, the United States...
02/25/2025
Neurology
fda building sign
News
FDA Approves Apomorphine Drug-Device for Movement Symptoms in Parkinson Disease
02/04/2025
Brionna Mendoza
The US Food and Drug Administration (FDA) approved a drug-device combination to treat movement-related symptoms in advanced Parkinson disease.
The US Food and Drug Administration (FDA) approved a drug-device combination to treat movement-related symptoms in advanced Parkinson disease.
The US Food and Drug...
02/04/2025
Neurology
a patient with parkinson disease steadies a tremoring hand and wrist
News
Propranolol Reduces Tremors in Parkinson Disease Patients
01/16/2025
Jolynn Tumolo
The beta-blocker propranolol reduces Parkinson disease (PD) tremor in both stressful and resting conditions, according to results from a placebo-controlled crossover trial published in the Annals of Neurology.
The beta-blocker propranolol reduces Parkinson disease (PD) tremor in both stressful and resting conditions, according to results from a placebo-controlled crossover trial published in the Annals of Neurology.
The beta-blocker propranolol...
01/16/2025
Neurology
FDA approval stamp
News
FDA Approves Infusion Treatment for Advanced Parkinson Disease in Adults
10/18/2024
Meagan Thistle
AbbVie’s VYALEV (foscarbidopa and foslevodopa), the first 24-hour continuous subcutaneous infusion of levodopa-based therapy for managing motor fluctuations in adults with advanced Parkinson disease (PD), approved by the FDA.
AbbVie’s VYALEV (foscarbidopa and foslevodopa), the first 24-hour continuous subcutaneous infusion of levodopa-based therapy for managing motor fluctuations in adults with advanced Parkinson disease (PD), approved by the FDA.
AbbVie’s VYALEV (foscarbidopa...
10/18/2024
Neurology
A person walks down a boarded path with sunlight and trees in the background
News
Phase 3 TEMPO-1 Trial Reports Positive Results on Tavapadon for Parkinson Disease
10/09/2024
Brionna Mendoza
Tavapadon, an investigational D1/D5 dopamine receptor partial agonist for Parkinson disease (PD), met both the primary and secondary endpoints in the phase 3 TEMPO-1 clinical trial.
Tavapadon, an investigational D1/D5 dopamine receptor partial agonist for Parkinson disease (PD), met both the primary and secondary endpoints in the phase 3 TEMPO-1 clinical trial.
Tavapadon, an investigational...
10/09/2024
Neurology
News
Parkinson Disease Risk Elevated in Patients With Upper GI Mucosal Damage
09/30/2024
Jolynn Tumolo
A history of upper gastrointestinal mucosal damage is associated with a 76% increased risk of subsequent Parkinson disease (PD), according to a study published online in JAMA Network Open.
A history of upper gastrointestinal mucosal damage is associated with a 76% increased risk of subsequent Parkinson disease (PD), according to a study published online in JAMA Network Open.
A history of upper...
09/30/2024
Neurology
A woman holds her forehead in pain with a migraine
News
No Link Found Between Migraine and Parkinson Disease, Contrary to Previous Findings
08/28/2024
Brionna Mendoza
A new cohort study involving female participants found no link between migraine and later Parkinson disease (PD) development. Findings from the study were published in Neurology.
A new cohort study involving female participants found no link between migraine and later Parkinson disease (PD) development. Findings from the study were published in Neurology.
A new cohort study involving...
08/28/2024
Neurology
An older woman sits alone
News
New-Onset Anxiety Increases PD Risk in Adults 50 and Older
08/27/2024
Jolynn Tumolo
The risk of developing Parkinson disease (PD) is doubled in adults 50 and older with new-onset anxiety compared with those without anxiety, according to a study published in the British Journal of General Practice.
The risk of developing Parkinson disease (PD) is doubled in adults 50 and older with new-onset anxiety compared with those without anxiety, according to a study published in the British Journal of General Practice.
The risk of developing Parkinson...
08/27/2024
Neurology
Dementia in PD May Occur Less Frequently Than Previously Thought
News
Dementia in PD May Occur Less Frequently Than Previously Thought
08/21/2024
Evi Arthur
Dementia occurrence in Parkinson disease (PD) may occur less frequently or take more time to develop than previous studies have shown, according to recent results from 2 ongoing prospective studies published in Neurology. 
Dementia occurrence in Parkinson disease (PD) may occur less frequently or take more time to develop than previous studies have shown, according to recent results from 2 ongoing prospective studies published in Neurology. 
Dementia occurrence in Parkinson...
08/21/2024
Neurology
Neurons in the brain
News
Risk Factors for Late-Onset Epilepsy in Patients With Cognitive Decline Identified
04/21/2025
Jolynn Tumolo
Late-onset epilepsy (LOE) risk factors in people with cognitive decline include Parkinson disease, early-onset dementia (before age 60), poor cognition, stroke or transient ischemic attacks, Alzheimer disease, and the APOE4 allele.
Late-onset epilepsy (LOE) risk factors in people with cognitive decline include Parkinson disease, early-onset dementia (before age 60), poor cognition, stroke or transient ischemic attacks, Alzheimer disease, and the APOE4 allele.
Late-onset epilepsy (LOE) risk...
04/21/2025
Neurology
FDA approval stamp
News
FDA Approves Diazepam Nasal Spray for Children Aged 2 to 5 With Seizure Clusters
04/16/2025
Meagan Thistle
The FDA has expanded approval of immediate-use diazepam nasal spray as an acute treatment of intermittent, stereotypic episodes of frequent seizure activity—also known as seizure clusters or acute repetitive seizures—in pediatric patients...
The FDA has expanded approval of immediate-use diazepam nasal spray as an acute treatment of intermittent, stereotypic episodes of frequent seizure activity—also known as seizure clusters or acute repetitive seizures—in pediatric patients...
The FDA has expanded approval of...
04/16/2025
Neurology
older woman on bed rest
News
Olfactory Deficits Signal Mortality Risk From Neurodegenerative Causes in Older Adults
04/14/2025
Jolynn Tumolo
Each additional incorrect answer by older adults on an odor identification test increased all-cause mortality risk by 6% over 6 years, according to a recent study.
Each additional incorrect answer by older adults on an odor identification test increased all-cause mortality risk by 6% over 6 years, according to a recent study.
Each additional incorrect answer...
04/14/2025
Neurology
image of the heart
News
After Stroke in Atrial Fibrillation, Earlier Oral Anticoagulant Initiation Appears Better
04/07/2025
Jolynn Tumolo
A clinical trial that investigated the best time within the recommended 14-day window to initiate treatment with a direct oral anticoagulant in patients with acute ischemic stroke with atrial fibrillation found no clearly superior day.
A clinical trial that investigated the best time within the recommended 14-day window to initiate treatment with a direct oral anticoagulant in patients with acute ischemic stroke with atrial fibrillation found no clearly superior day.
A clinical trial that...
04/07/2025
Neurology
a human hand holds a Vitamin D supplement pill against a background of clouds in the sky on a sunny day
News
High-Dose Vitamin D Eases Disease Activity in Patients With Multiple Sclerosis
03/20/2025
Jolynn Tumolo
High-dose vitamin D reduced disease activity over 24 months in patients with clinically isolated syndrome typical for multiple sclerosis (MS) and early relapsing-remitting MS, according to study results published in JAMA.
High-dose vitamin D reduced disease activity over 24 months in patients with clinically isolated syndrome typical for multiple sclerosis (MS) and early relapsing-remitting MS, according to study results published in JAMA.
High-dose vitamin D reduced...
03/20/2025
Neurology
illustrated brain with brain waves against a black background
News
Tool Gauges a Patient’s Epilepsy Status From a Single Normal EEG
03/12/2025
Jolynn Tumolo
A newly developed tool uses algorithms trained on dynamic network models to identify hidden markers of epilepsy from a single routine scalp electroencephalogram (EEG), according to a study published in the Annals of Neurology.
A newly developed tool uses algorithms trained on dynamic network models to identify hidden markers of epilepsy from a single routine scalp electroencephalogram (EEG), according to a study published in the Annals of Neurology.
A newly developed tool uses...
03/12/2025
Neurology
fda building sign
News
FDA Approves First New Stroke Drug, Tenecteplase, in Nearly 30 Years
03/04/2025
Brionna Mendoza
The US Food and Drug Administration (FDA) has approved tenecteplase (TNKase®), a thrombolytic agent developed by Genentech, for the treatment of acute ischemic stroke (AIS) in adults.
The US Food and Drug Administration (FDA) has approved tenecteplase (TNKase®), a thrombolytic agent developed by Genentech, for the treatment of acute ischemic stroke (AIS) in adults.
The US Food and Drug...
03/04/2025
Neurology
A doctor and patient talk
News
Later Life Depressive Symptoms Not Linked With Amyloid Accumulation
03/04/2025
Jolynn Tumolo
In older adults with normal cognition, depressive symptoms were not consistently associated with amyloid pathology. Meanwhile, depressive symptoms were associated with a reduced likelihood of amyloid pathology in older adults with mild...
In older adults with normal cognition, depressive symptoms were not consistently associated with amyloid pathology. Meanwhile, depressive symptoms were associated with a reduced likelihood of amyloid pathology in older adults with mild...
In older adults with normal...
03/04/2025
Psych Congress Network
A woman lies on the couch holding an ice pack to her head
News
Mild TBI Sustained in Traumatic Context Associated With Worse Long-Term Outcomes
03/03/2025
Jolynn Tumolo
Mild traumatic brain injury (mTBI) that occurred in the context of psychological trauma was associated with poorer long-term outcomes, including greater posttraumatic stress disorder (PTSD) severity, postconcussive symptoms, and disability.
Mild traumatic brain injury (mTBI) that occurred in the context of psychological trauma was associated with poorer long-term outcomes, including greater posttraumatic stress disorder (PTSD) severity, postconcussive symptoms, and disability.
Mild traumatic brain injury...
03/03/2025
Neurology
An illustration of a brain against a blue background, with a deep brain stimulation device connected via electrodes
News
FDA Approves ‘Self-Adjusting’ DBS Therapy for Parkinson Disease
02/25/2025
Brionna Mendoza
On Monday, the United States Food and Drug Administration (FDA) approved an adaptive deep brain stimulation (aDBS) technology for people living with Parkinson disease (PD).
On Monday, the United States Food and Drug Administration (FDA) approved an adaptive deep brain stimulation (aDBS) technology for people living with Parkinson disease (PD).
On Monday, the United States...
02/25/2025
Neurology

Alzheimer's Disease CME Series

Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources
11/19/2020
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources To view accreditation information/faculty disclosures for the program, click 
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources To view accreditation information/faculty disclosures for the program, click 
Early Alzheimer’s Disease:...
11/19/2020
Neurology
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources
11/19/2020
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient ResourcesOnline Form - PBHLN-NLN Alzheimers Video Series
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient ResourcesOnline Form - PBHLN-NLN Alzheimers Video Series
Early Alzheimer’s Disease:...
11/19/2020
Neurology
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources
11/19/2020
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient ResourcesTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click...
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient ResourcesTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click...
Early Alzheimer’s Disease:...
11/19/2020
Neurology
Emerging Treatments for Early Alzheimer Disease: Efficacy and Safety Data
11/17/2020
Emerging Treatments for Early Alzheimer Disease: Efficacy and Safety Data To view accreditation information/faculty disclosures for the program, click 
Emerging Treatments for Early Alzheimer Disease: Efficacy and Safety Data To view accreditation information/faculty disclosures for the program, click 
Emerging Treatments for Early...
11/17/2020
Neurology
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety Data
11/17/2020
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety Data Online Form - PBHLN-NLN Alzheimers Video Series
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety Data Online Form - PBHLN-NLN Alzheimers Video Series
Emerging Treatments for Early...
11/17/2020
Neurology
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety Data
11/17/2020
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety DataTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation...
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety DataTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation...
Emerging Treatments for Early...
11/17/2020
Neurology
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of Action
11/12/2020
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of Action To view accreditation information/faculty disclosures for the program, click 
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of Action To view accreditation information/faculty disclosures for the program, click 
Emerging Treatments for Early...
11/12/2020
Neurology
Early Alzheimer’s Disease Overview: Burden of Disease, Quality-of-Life Impacts, and Pathophysiology
11/12/2020
Early Alzheimer’s Disease Overview: Burden of Disease, Quality-of-Life Impacts, and Pathophysiology Online Form - PBHLN-NLN Alzheimers Video Series
Early Alzheimer’s Disease Overview: Burden of Disease, Quality-of-Life Impacts, and Pathophysiology Online Form - PBHLN-NLN Alzheimers Video Series
Early Alzheimer’s Disease...
11/12/2020
Neurology
Claim-Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of Action
11/12/2020
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of ActionTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation button...
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of ActionTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation button...
Emerging Treatments for Early...
11/12/2020
Neurology
Current Treatment Limitations and Clinical Needs in Early Alzheimer’s Disease
11/10/2020
Current Treatment Limitations and Clinical Needs in Early Alzheimer’s Disease To view accreditation information/faculty disclosures for the program, click 
Current Treatment Limitations and Clinical Needs in Early Alzheimer’s Disease To view accreditation information/faculty disclosures for the program, click 
Current Treatment Limitations...
11/10/2020
Neurology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use